Independent · non-commercial · publishes on a quarterly cycle|Current cycle 2026 Q3
Compound Evidence InstituteEvidence synthesis · established 2023Graded assessments of compounds, trials, methods and supply
Document set current to 30 July 2026
Public comment period · Document series

Draft format of the supplier dossier series

Consultation on the format of the supplier dossier series: what a dossier contains, in what order, and what it declines to contain. The draft fixes a common structure so that two dossiers can be read against each other, and excludes any field the Institute…

Document identifier
CEI-CP-020
Series
Public comment period
Version
1.0
Published
11 Apr 2024
Last reviewed
11 Apr 2024
Next review
11 Apr 2025
Identifier
10.71829/cei.cp.20
Certainty
Not rated
Cycle
2024 Q1
Window
27 Jan 2024 – 27 Mar 2024
Status
Closed
Submissions
10

§1Consultation and window

§1.1Window

Opened
27 January 2024
Closed
27 March 2024
Duration
60 days
Status
Closed — the disposition is published
Document under consultation
Document series
Submissions received
10

§1.2Consultation questions

The secretariat put the following questions. A submission was not required to address them and several did not; the questions record what the Institute was uncertain about rather than restricting what a respondent could raise.

  1. Is the fixed structure workable across suppliers that differ substantially in the documentation they publish?
  2. Should a dossier record a field the Institute could not verify, marked as unverified, or omit it?
  3. Is the relationship between a dossier and the rubric score stated clearly enough for a reader who arrives at the dossier first?

§1.3How a submission is handled

  • Every submission is signed. The Institute publishes no anonymous submission.
  • Every submission carries a declared interest. A declaration of no interest is itself a declaration and is recorded as one. A declaration is not a disqualification and the Institute has never given a submission less weight on that ground.
  • A submission from an employee of a marketing-authorisation holder is identified as an industry submission on its face, following a unanimous consultation on the conflicts policy.
  • Every submission receives a secretariat response and a disposition. Submissions that are not accepted remain published in full; the Institute does not remove a submission because it disagrees with it.
  • There is no voting, no reputation score, no reply thread and no editing after receipt.

§1.4Outcome

The series format was ratified with amendments. An unverifiable field is now recorded and marked rather than omitted, because an omission is indistinguishable from an absence, and the rubric relationship is stated at the head of every dossier.

The disposition table, listing each submission with its disposition and the resulting amendment, is at §3.

Nothing published by the Institute is medical advice, a diagnosis, a prescription, a treatment recommendation or a purchasing recommendation. Compounds supplied for research use are not approved for human or veterinary use in any jurisdiction, and a favourable analytical assessment of a supplier is not a statement that any product is safe or effective. The Institute publishes certainty ratings and never recommendations. No telephone number, messaging handle or ordering channel appears anywhere on this site.